The impact of insulin on PD-L1 mediated immune evasion of PDAC also represents a novel pathophysiological mechanism that provides another rational for using anti-diabetic medications like metformin [57,58] also in the treatment of PDAC, thereby abrogating the immune privilege of PDAC cells due to hyperinsulinemia. The gene discussed is INS; the disease is Hyperinsulinemia.